Cohen & Steers, Inc.
CNS
Updated: 24/09/2026, 16:55:51
Cohen & Steers, Inc. operates as a publicly traded holding company specializing in asset management. Through its various operating units, the firm delivers financial services to institutional investors, such as pension funds, university endowments, and charitable foundations. Its subsidiaries are tasked with managing bespoke client portfolios across equities, fixed income, multi-asset strategies, and commodities. Additionally, these subsidiaries develop and oversee a diverse range of investment vehicles, including mutual funds (focused on equity, fixed income, balanced, and multi-asset classes) and hedge funds. The company's global investment strategy, implemented via its affiliated entities, involves allocating capital in public equity, fixed income, and commodity markets. For its equity and fixed income allocations, the firm's affiliates specifically target businesses within the real estate industry (including REITs), infrastructure, and natural energy resources. Preferred securities also constitute a part of its fixed income portfolios. Established in 1986, Cohen & Steers, Inc. maintains its primary base in New York, with international branch offices in London (UK), Central (Hong Kong), Tokyo (Japan), and Seattle (Washington).
No summaries found.
- Share price
- $75.07
- Market cap
- $3.86B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Joseph Martin Harvey
- Employees
- 424
- IPO date
- 16/08/2004
- Beta
- 1.197
- Last dividend
- $0.00
- Day range
- $74.98 – $76.79
- 52-week range
- $58.39 – $86.56
- 1-day performance
- -0.50%
- 1-year performance
- 28.56%
- Current drawdown (1Y)
- -13.28%
- CIK
- 0001284812
- CUSIP
- 19247A100
- ISIN
- US19247A1007
- Created
- 07/12/2025, 03:23:25
- Last update
- 24/09/2026, 16:55:51
Track Cohen & Steers, Inc. with an AI analyst
See which prediction-market events move CNS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
GlobeNewsWire • STOCK • 11/06/2026, 09:00:00
Cohen & Steers Quality Income Realty Fund, Inc. Declares Distributions for July, August, and September 2026
PRNewsWire • STOCK • 08/06/2026, 18:20:00
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2026
PRNewsWire • STOCK • 08/06/2026, 18:15:00
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Accesswire • STOCK • 08/06/2026, 11:15:00
Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline
MarketBeat • STOCK • 06/06/2026, 02:02:38
Cohen & Steers Appoints Amit Muni as Chief Financial Officer
PRNewsWire • STOCK • 21/05/2026, 18:30:00
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Accesswire • STOCK • 20/05/2026, 11:02:00
Cohen & Steers Income Opportunities REIT, Inc. Acquires Shopping Center in Charlotte, North Carolina
PRNewsWire • STOCK • 13/05/2026, 10:45:00
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for April 2026
PRNewsWire • STOCK • 11/05/2026, 18:20:00
Cohen & Steers Announces Changes to Realty Indexes
PRNewsWire • STOCK • 08/05/2026, 19:35:00
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
GlobeNewsWire • STOCK • 08/05/2026, 09:30:00
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
PRNewsWire • STOCK • 04/05/2026, 11:35:00